Back to Peptide Library
Thymic Bioregulator

Vilon

KE Dipeptide • Thymic Signaling • Immune-Aging Research

Vilon is the Lys-Glu (KE) dipeptide studied in thymic-cell and aging-related chromatin models. Its proposed immune effects remain laboratory findings; clinical benefits from injectable Vilon have not been established.

Routes
SubQ research
Compound type
KE dipeptide
Regulatory status
Not FDA approved
Last reviewed
At a glance

Vilon Quick Reference

Community research dose
200mcg–1mg daily
No validated human dose
Reported route
SubQ injection
Community convention, not an approved route
Reported cycle
10–20 days
Repeat timing varies
Research focus
Thymic and chromatin signaling
Cell studies; clinical benefit unproven
Overview

What Is Vilon?

Vilon is a synthetic dipeptide made of lysine and glutamic acid (Lys-Glu, or KE). It emerged from the short-peptide bioregulator research associated with Vladimir Khavinson and has been investigated mainly in thymic-cell and lymphocyte models.

Laboratory work has reported changes in immune-cell differentiation markers, cell proliferation, and chromatin organization. These experiments do not show that injected Vilon improves immunity, recovery, or aging outcomes in people.

Mechanism

Vilon Mechanism of Action

Thymic-Cell Response

In cultured human and animal thymic cells, Vilon and related dipeptides changed the expression of CD5, a lymphocyte differentiation marker. This is a cell-model signal, not a demonstrated immune benefit. Thymic-cell study.

Chromatin Organization

Studies of cultured lymphocytes from older adults reported decondensation of several chromatin regions after Vilon exposure. They did not establish an anti-aging effect in living people. Lymphocyte study.

Cell Proliferation

An experimental thymocyte study observed increased markers of protein synthesis and transformation into proliferating cells. The relevance to human health is unknown. Thymocyte study.

Immune-Aging Hypothesis

These findings motivate research into age-related immune signaling. They do not establish that injectable Vilon prevents illness or restores immune function.

Research findings

Vilon Benefits

Vilon research points to cell-level effects rather than established benefits in people. The strongest direct evidence comes from thymic-cell and cultured-lymphocyte experiments.

Current evidence level: laboratory and preclinical

Thymic-Cell Signaling

Cultured thymic cells showed changes in a lymphocyte differentiation marker after exposure to Vilon.

Chromatin Research

Older-adult lymphocyte cultures showed decondensation of some chromatin regions; this is not a proven clinical anti-aging outcome.

Cell-Activity Models

Experimental thymocyte work reported changes in protein-synthesis and proliferation markers.

Immune-Aging Interest

The peptide is investigated as a candidate for age-related immune signaling, with no established benefit in humans.

Protocol planning

Vilon Dosing Protocol

There is no validated human Vilon dose or cycle. The range below describes community research practice and should not be confused with a clinically tested protocol.

Community research range200mcg–1mg daily
Lower range
200–400mcg daily in community protocols.
Middle range
500–750mcg daily is also discussed.
Cycle
Typically 10–20 days, with repeat cycles several months apart.
Evidence limit
Modern human dose-finding and injectable safety studies are unavailable.
Preparation

Vilon Reconstitution

Example concentration

20mg vial + 3mL bacteriostatic water

Result6.67mg/mL

Reconstitution steps

1
Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2
Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

3
Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

4
Store

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

Vilon Community Experience

Self-reported anecdotal experiences from peptide communities and anonymous site reports. These accounts do not carry the weight of published research.

Positive Reports

  • Energy and resilience. Some users report steadier daily energy or activity tolerance.
  • Recovery perception. Some describe less soreness and better training readiness.
  • Repeat-cycle interest. Vilon appears in short-cycle bioregulator discussions, often alongside other compounds.

Negative & Mixed Reports

  • No obvious effect. Some users report little or no change.
  • Stacking obscures attribution. Reports involving multiple peptides cannot isolate Vilon’s contribution.
  • Occasional discomfort. Fatigue, headache, injection-site irritation, or increased heart rate appear in some reports.
Stacking & synergy

Vilon Stacking & Synergy

No controlled trials establish Vilon combination benefits. These are community-discussed pairings; the compounds should be evaluated separately when interpreting a report.

Vilon + Thymosin Alpha-1

Both are discussed in immune research, but their proposed pathways and evidence bases differ. Effects of the combination are unknown.

Vilon + Epitalon

A bioregulator pairing discussed around immune aging and circadian research; no controlled Vilon combination study validates it.

Vilon + Pinealon

A community pairing spanning thymic and neural bioregulator concepts. Any reported benefit is hard to attribute to either compound.

Safety notes

Vilon Side Effects & Safety

Compound-specific human safety data are sparse. The absence of a clear adverse-event signal in small studies does not establish the safety of injectable Vilon.

Long-term immune effects, interactions, and safety in people using injectable Vilon have not been characterized.

Community Reports

  • Many reports describe no obvious acute effect.
  • Headache, fatigue, and injection-site redness or irritation are occasionally reported.
  • A few accounts mention a noticeable increase in heart rate.

Unknowns

  • No modern long-term injectable safety program is available.
  • Formal interaction studies have not been conducted.
  • Immune-related risks in people with autoimmune disease, transplants, or active cancer remain unknown.

Vilon Precautions

Avoid or Discuss With a Clinician If
  • Pregnant or breastfeeding; safety data are unavailable.
  • Known hypersensitivity to Vilon or its components.
  • Active cancer, immune deficiency, autoimmune disease, or a transplant history.
Use caution with
  • Immunosuppressants, biologic therapies, or other immune-modulating compounds.
  • Any complex stack that makes adverse effects difficult to identify.
Regulatory status: Vilon is not FDA approved, and no established therapeutic dose or approved injectable use exists.
Final verdict

Peptide Protocols Verdict on Vilon

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion

Vilon is one of the more interesting bioregulators to us. Our experience and community feedback suggest steadier energy, less soreness, and better daily recovery for some people, though these reports are subjective and often involve stacks.

Pairing it with Pinealon and Epitalon creates a coherent bioregulator theme, but we cannot tell how much any one compound contributes. The short-cycle format is practical for tracking.

We remain interested in Vilon while recognizing the gap between cell research and proven human outcomes. The community signal is encouraging; controlled trials and better injectable safety data are still needed.